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The incidence of hormone-related cancers tends to be higher in the developed world than in other countries. In Slovenia, 
six hormone-related cancers (breast, ovarian, endometrial, prostate, testicular, and thyroid) account for a quarter of all 
cancers. Their incidence goes up each year, breast and prostate cancer in particular. The age at diagnosis is not decreasing 
for any of the analysed cancer types. The risk of breast cancer is higher in the western part of the country, but no differences 
in geographical distribution have been observed for other hormone-related cancers. Furthermore, areas polluted with 
endocrine-disrupting chemicals that affect hormone balance such as PCBs, dioxins, heavy metals, and pesticides, do not 
seem to involve a greater cancer risk. We know little about how many cancers can be associated with endocrine disruptors, 
as there are too few reliable exposure studies to support an association.
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Sex hormones have been associated with breast, ovarian 
and, endometrium cancers, while their role in prostate and 
testicular cancers is not as clear (1). The thyroid axis 
hormones and oestrogens may also take part in the 
development of thyroid cancer (2). These six cancer types 
are usually referred to as hormone-related cancers (HRCs) 
(1-3) because they share the same mechanism of 
carcinogensis. In addition, there is accumulating evidence 
that sex hormones also play a role in the aetiology of 
colorectal (4) and liver cancer (5). Relatively high 
concentrations of oestrogen receptor are also present in the 
spleen, while low levels have been detected in the kidney, 
thymus, skin, and lung (6). However, these cancer types 
are generally (and in our evaluation) not considered as 
HRCs (1).
Epidemiological evidence of the association between 
endogenous and exogenous hormones with cancer comes 
from a variety of sources: from geographical differences in 
cancer risk, from migration studies, from time trend 
analyses of incidence and mortality data and from analytical 
studies comparing populations being exposed and not being 
exposed to a selected factor (1-3). Global rates of HRCs 
have been increasing over the past 40-50 years (3) and are 
the highest in industrialised countries (7). There is an 
indication that age at exposure is especially important, as 
there are periods of greater vulnerability during development 
(such as foetal and prepubertal exposure) (8).
Endocrine disruptors that are most commonly associated 
with HRCs are polychlorinated biphenyls (PCBs), dioxins, 
some heavy metals, and pesticides (such as DDT and DDE). 
Table 1 lists the groups of endocrine disruptors associated 
with HRCs. Many of these association studies are 
inconclusive because they typically suffer from 
methodological limitations such as measurement of 
exposure at wrong time or disregard of combined exposure 
(2) .  For  example,  several  organochlorine and 
organophosphate pesticides have been linked with an 
increased risk of prostate cancer, especially in occupational 
studies, but only two pesticides [inorganic arsenic 
compounds and dioxin TCDD (tetrachlorodibenzo-p-
dioxin)] had strong enough evidence to be classified as 
carcinogenic to humans (IARC Group 1) (1). Five 
organophosphate pesticides have recently been moved from 
the IARC Group 3 (not classifiable) to Group 2 (probably 
carcinogenic to humans), because there is enough evidence 
that they are carcinogenic in animals. However, evidence 
from human studies is scarce and inadequate to classify 
these pesticides as IARC Group 1 (9).
We focused our study on the overall, geographical, and 
age-specific incidence of six HRCs in Slovenia over the 
last 50 years. In addition, we put the national statistics in 
an international context and looked for the reasons for 
changes in epidemiological indices, paying particular 
attention to the potential influence of exogenous hormones 
and hormone-like substances.
Latest research in Slovenia (original data)
Our latest research included 77,271 HRC cases 
diagnosed in Slovenia between 1961 and 2011, as reported 
by the Slovenian population-based cancer registry.
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Cancer Registry of the Republic of Slovenia (CRS) is 
one of the oldest population-based cancer registries in the 
world. Reporting cancer has been mandatory in Slovenia 
since the CRS’s foundation in 1950. Cancer data collection 
complies with all international standards and covers 100 % 
of the population (10). Data quality (reliability and 
completeness) is regularly monitored and published in 
CRS’s annual reports (11). The ratio between mortality and 
incidence has been stable over the years. The proportion of 
cases registered based on death certificate only has not 
exceeded 2 % for several decades. More than 90 % of the 
registered cases have been confirmed by microscopy. To 
verify personal information and monitor the vital status of 
patients, CRS has access to the national population registry, 
while it updates patient residence data from the national 
Register of Spatial Units (maintained by the Surveying and 
Mapping Authority of Slovenia). Population demographics, 
stratified by gender and five-year age groups, is updated 
regularly from the Statistical Office of the Republic of 
Slovenia.
CRS provides information on the incidence, prevalence, 
and survival of cancer patients. Cancer sites are coded 
according to the 10th revision of the International Statistical 
Classification of Diseases and Related Health Problems 
(ICD10). Our study has included incidence data on the 
following HRCs: breast (ICD10: C50; analysed for women 
only), endometrial (ICD10: C54), ovarian (ICD10: C56 and 
D39.1 encoding ovarian tumours of borderline malignancy), 
prostate (ICD10: C61), testicular (ICD10: C62), and thyroid 
cancer (ICD10: C73). Ovarian tumours of borderline 
malignancy (D39.1) have been classified separately at the 
CRS from the year 2001 on, but we’ve merged both types 
of ovarian tumour for this analysis.
Incidence rates were age-standardised (ASR) to the 
European Standard Population using the following formula:
where N is the number of cases in the observed population, 
P is the number of persons in the observed population, S is 
the number of persons in the standard population and i is a 
five-year age group. ASRs are presented by the calendar 
year of diagnosis. The time trends of ASRs for each 
examined cancer site were analysed using log-linear 
joinpoint regression (12). The trends were characterised in 
terms of average annual percent change (APC), assuming 
a constant rate of the previous year. In addition, a 95 % 
confidence interval (CI) of APC is reported. To check if the 
age at cancer onset is decreasing, we calculated age-specific 
incidence rates for four age groups: 15-39 years, 40-54 
years, 55-69 years, and 70 or more years. In addition, we 
determined the time trend of the median age at diagnosis 
for all patients younger than 55 at diagnosis.
Review of the latest research results and earlier research 
in Slovenia
The six HRCs account for almost a quarter of all cancers 
in the developed countries (including non-melanoma skin 
cancers). In Europe, their annual age-standardised incidence 
is 80.4 per 100,000 men and 110.4 per 100,000 women (7). 
The annual number of new cases and ASR rates for Slovenia 
is reported in Table 2. With more than 20 % of all cancer 
cases, breast and prostate cancers are the most common 
cancers diagnosed in women and men, respectively. 
Endometrial and ovarian cancers rank 5th to 10th in incidence 
among women. Testicular cancer is generally rare but is the 
most common cancer among young and middle-aged men. 
Thyroid cancer is also relatively uncommon but is 
approximately four times more frequent in women.
Incidence trends
Figure 1 shows that the incidence of prostate, breast, 
endometrial, testicular, and thyroid cancers have been on 
the rise, whereas ovarian cancer has been stable over the 
investigated 50 years. Average annual percent changes in 
Table 2 give a better view of the increases in incidence from 
1992 to 2011 for each investigated HRC. Prostate cancer 
clearly leads, followed by thyroid and testicular cancer. 
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Table 1 Groups of chemicals associated with hormone-related cancers (adopted from ref. 2)
 Breast Endometrium Ovary Prostate Testis Thyroid
Polychlorinated biphenyls, dioxins, furans x   x x x
Polybrominated diphenyl ethers     x  
DDT/DDE x x  x x  
Pesticides x  x x x x
Heavy metals x x  x   
Bisphenol A, parabens x x    x
Phthalates     x  
Pharmaceutical estrogens x x x x x x
Phytoestrogens x   x  x
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years. Figure 2 shows that the incidence of breast, 
endometrial, and prostate cancers is rising in the population 
aged 55 and over. Ovarian cancer is dropping in women 
older than 40, but the trend seems stable in women of 
younger ages. Thyroid cancer, in turn, shows a comparable 
increase in age groups up to 69 and a plateau from 70 years 
up.
For any of the analysed HRCs the median age at 
diagnosis in patients diagnosed before the age of 55 has not 
decreased in the last twenty years. On the contrary, it has 
risen by one year for prostate, testicular, and ovarian cancers 
(to 51, 33, and 48 years, respectively). As for breast cancer, 
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Breast cancer incidence, in turn, was the most prominent 
between 1992 and 1999 (APC: 3.8, CI 2.1;5.5), since which 
time it has stabilised (APC: 0.5, CI -0.2;1.2). Endometrial 
cancer incidence has not changed over the last twenty years, 
and ovarian cancer has shown a rise of only 0.7 % per year.
Age at diagnosis
With the exception of testicular cancer, where the age-
specific incidence rates are the highest between 25 and 35 
years, all other HRCs develop at a later age, most frequently 
after the age of 60. Our time-trend analysis of the age at 
diagnosis did not indicate any earlier cancer onset in recent 
Figure 1 Age-standardised incidence rates for six hormone-related cancers by calendar year, Slovenia 1961-2011
Table 2 Average annual number of new cases (incidence) and age-standardized incidence rates (ASR) for six hormone-related cancers 
in Slovenia between 2009 and 2011. Average annual percent change of ASR for the six HRCs between 1992 and 2011
Cancer Average incidence  (2009-2011)
Average ASR  
(2009-2011)
Annual percent change (95 % CI) 
(1992-2011)
Breast 1190 88.0 1.5 (1.1;2.0)
Endometrium 305 21.0 0.1 (-0.5;0.7)
Ovary 158 16.3 0.7 (0.1;1.3)
Prostate 1426 117.6 6.4 (5.7;7.1)
Testis 100 9.1 3.4 (2.3;4.5)
Thyroid 150 6.4 5.2 (4.2;6.1)
ASR: age standardized incidence rate per 100,000 person years (European standard)
CI: confidence interval
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the median age at diagnosis for patients diagnosed before 
55 has been 47 for the last twenty years. In the younger age 
group, it also has not changed: the median for the groups 
diagnosed before 35 and before 25 has been 33 and 23 years, 
respectively.
Geographical distribution
The GLOBOCAN 2012 statistics (7) indicate that the 
incidence of all HRCs varies significantly worldwide. As a 
rule, their incidence is higher in the industrial world and 
remains low in many parts of Asia and Africa. The incidence 
of prostate, testicular, endometrial, ovarian, and thyroid 
cancer varies by more than 25-fold across the world’s 
regions. For prostate cancer this variation primarily reflects 
the differences in the availability of prostate-specific antigen 
(PSA) screening, but for other cancers the variation may 
reflect differences in lifestyle and genetic factors, as 
described in more detail in Discussion. Variations in breast 
cancer incidence are smaller (nearly fourfold), with rates 
ranging from 27 per 100,000 in Middle Africa and Eastern 
Asia to 96 in Western Europe.
HRC incidences do not vary as much between European 
regions. According to the EUCAN database (13), the 
variation is the highest for thyroid cancers (over tenfold), 
with the highest incidence in Austria, Italy, and Lithuania 
(12-15 per 100,000) and the lowest in Albania, Bosnia and 
Hercegovina, and Greece (1 per 100,000) (13). Cancer 
mapping of the Alpine regions (14) shows no geographical 
variation for endometrial and ovarian cancers. The highest 
prostate cancer incidence is reported in Austrian communities 
where PSA testing is extensive, whereas breast cancer 
incidence is the highest in Italian communities. In an earlier 
research (15), Zadnik observed variations in breast cancer 
incidence between Slovenian west and east (highest to 
Figure 2 Age-specific incidence rates for six hormone-related cancers by calendar year, Slovenia 1961-2011
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lowest, respectively) (Figure 3). As for other HRCs, we 
observed no geographical variations.
Recently, we investigated the relationship between 
cancer burden, environmental pollution and carcinogenic 
endocrine disruptors (16, 17). The analyses of cancer 
incidence in Bela krajina, which is heavily polluted with 
PCBs (16) and of the Celje region, polluted with heavy 
metals (17) have not established any significant increase in 
the risk of any HRCs among the population living in these 
areas.
Risk factors for the development of HRCs include 
reproductive characteristics associated with oestrogen and 
other hormones, pharmaceutical hormones, and lifestyle, 
such as alcohol use and lack of exercise. Below we are 
going to discuss the reasons that may have led to the rise 
in HRC burden established in this study, paying particular 
attention to the potential influence of exogenous hormones 
and hormone-like substances.
Review of risk factors for HRC development
Female breast cancer
The first to report high incidence of breast cancer in 
nuns more than three hundred years ago was Bernardo 
Ramazzini in his De Morbis Artificum Diatriba (in chapter 
“De Nutricum Morbis”), pointing to the association between 
reproduction and cancer risk. Today we know that breast 
cancer risk is twice as high in nulliparous women as in the 
parous women. It is the lowest in women who have given 
birth at an early age (full term pregnancy) and rises with 
age (18). In fact, women who give birth at the age 30 or 
later run a higher risk than nulliparous women.
Furthermore, breast cancer risk drops with breastfeeding. 
Women who have given birth and breastfed several children 
over long time run the lowest risk (19, 20).
Menstrual factors are also very important in predicting 
breast cancer risk. Menarche at an early age and menopause 
at a later age are associated with the highest risk, presumably 
due to ovulation activity and changes in endogenous 
hormonal profiles (21, 22).
Physical activity and obesity may also be related to 
breast cancer risk. Obesity is associated with higher risk of 
post-menopausal breast cancer. In premenopausal women 
obesity-related anovulation seems to reduce the risk, and 
the conversion of androgens to oestrogens in adipose tissue 
after menopause seems to increase the risk (1, 21, 23).
Physical activity has been associated with a 23-30 % 
decrease in breast cancer risk. Some studies have focused 
on investigating the biological mechanisms mediating this 
association (23). Physical activity decreases endogenous 
oestrogens, fat-related insulin resistance, inflammation, and 
improves adipokine production (leptin and adiponectin) by 
reducing fat tissue, which are all independently associated 
with increased breast cancer risk (23, 24). Physical activity 
also seems to reduce oxidative stress and genomic 
instability; in postmenopausal women exercise decreases 
circulating oestrogen levels through weight loss (23-25).
Menopausal hormone replacement therapy has been 
associated with increased breast cancer risk among post-
menopausal women, especially in thin women (26). 
However, the major risk predictor is the type of hormones 
used; oestrogen plus progestogen seem to be associated 
with the highest risk.
Oral contraceptives are associated with increased risk 
of breast cancer especially among young women, but it falls 
to baseline after 10 years of discontinuation and is the same 
as in non-users (26).
According to Barnes et al. (27), the population-
attributable risk for non-modifiable breast cancer risk 
factors (age at menarche, age at menopause, parity, benign 
breast disease and family history of breast cancer) is 37.2 % 
for all invasive tumours considered. Among the modifiable 
risk factors, hormone therapy and physical inactivity 
contribute the most 19.4 % and 12.8 %, respectively.
Only 3-5 % of breast cancer is due to hereditary 
predisposition. BRCA1 and BRCA2 genes have been 
identified to be responsible for the majority of hereditary 
breast cancer. Carriers of germline mutations in BRCA1/2 
genes are at high risk of developing breast and/or ovarian 
cancer (28, 29). Several moderate and low penetrant genes 
have also been identified, and their role is still under 
investigation (29).
Endometrial cancer
Hormones play an important role in the aetiology of 
endometrial cancer, which is believed to arise from 
oestrogen stimulation that is unopposed by progestins (1). 
More than 80 % of cases of endometrial cancers are 
oestrogen-related. Obesity and menopausal hormone 
therapy are strong risk predictors, as well as early age at 
menarche, late age at menopause, and nulliparity. Oral 
contraceptives are associated with a long-lasting decrease 
in endometrial cancer risk only if they contain progestogen 
in addition to oestrogen (30). Unopposed oestrogen use in 
hormone replacement therapy is associated with a 
remarkably high risk (two to tenfold increase) which 
depends on the duration of use and the woman’s body mass 
(higher in thin women) (31). Obesity is associated with 
annovulatory cycles in premenopausal women, so the 
endometrial tissue receives continuous stimulation. In post-
menopausal women, the concentration of endogenous 
oestrogens increases in obese women. Endogenous 
oestrogens are mainly the product of androgen aromatisation 
in the fat tissue. Furthermore, excess weight is associated 
with insulin resistance and chronically elevated insulin 
concentration and increased concentrations of sex steroids 
(32) - all these factors are associated with higher endometrial 
cancer risk. Higher risk is also observed in patients with 
type 1 and type 2 diabetes. Other clinical features are also 
associated with higher risk such as polycystic ovary 
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syndrome (associated with increased blood androgen 
levels), infertility, amenorrhea, hirsutism, and tamoxifen 
therapy (twofold increase compared to non-users) (1).
Two to five percent of endometrial cancers are 
associated with hereditary syndromes such as Lynch (most 
frequent), Muir-Torre, Cowden, and the BRCA1 syndrome. 
Patients with Lynch syndrome who carry germline 
mutations in mismatch repair genes (mostly MLH1, MSH2, 
MSH6) face a 40-60 % lifetime risk of endometrial cancer 
(1).
Ovarian cancer
Nulliparity and infertility are well-known risk factors 
for ovarian cancers. Another predictor of some types of 
ovarian cancers (clear cell and endometroid cancers) is 
endometriosis (33). Beside hormonal factors (elevated 
gonadotropin levels), some irritants (talc, asbestos) seem 
to increase the risk of ovarian cancer.
The risk, however, drops with suppressed ovulation (by 
pregnancy or oral contraceptives; both lower pituitary 
gonadotropins) (34, 35). Substantially reduced risks have 
been observed in women who had simple hysterectomy or 
tubal ligation. While reduced ovulation is known to diminish 
the risk, it does not explain all of the identified risk factors. 
Latest research points to hormonal and immunological 
factors (36).
A very important risk factor is family history, since it 
accounts for about 10 % of cases. The risk increases 
threefold when two or more first-degree relatives have been 
diagnosed with ovarian cancer. Furthermore, women who 
carry germline mutations in BRCA1/2 genes and women 
with Lynch syndrome have a 30-70 % lifetime risk of 
developing ovarian cancer (37, 38).
Prostate cancer
Epidemiological studies, numerous as they are, seem 
to have failed to pinpoint all the causes of prostate cancer. 
We know that the risk increases with age, and is race and 
family history related (1). About 25 % of men with prostate 
cancer have a known family history of this cancer (39). 
Furthermore, in a twin cohort study (40) 42 % of prostate 
cancer cases were inheritable.
For a number of other probable exogenous risk factors 
such as alcohol, smoking, vasectomy, body mass index, 
exposure to certain chemicals in the workplace, the 
connection to prostate cancer has been evaluated but not 
confirmed. Agricultural workers have been identified as 
having a higher risk of prostate cancers, most probably 
because of their exposure to pesticides (1).
Among protective factors stand out specific diets such 
as those rich in carotenoid lycopene (41) or phytoestrogens 
that have been associated with lower incidence of prostate 
cancer in Asia (42).
Sex hormones are undoubtedly involved in the aetiology 
of prostate cancer, but the mechanism is still unclear. 
Epidemiological studies have ruled out the association with 
serum testosterone (1). It is most likely that changes in the 
metabolism or transfer of hormones on the cellular level 
are  involved in prostate  cancer  development . 
Pharmacological inhibitors of 5-alpha reductase lower the 
risk (43) whereas insulin-like growth factor seems to 
increase it (1).
The enormous increase in the incidence of prostate 
cancer in the developed countries in the last twenty years 
has mainly been attributed to the intensive use of screening 
with the PSA. PSA screening has increased the detection 
of all prostate cancers, including indolent prostate cancers. 
It has nearly doubled the diagnosis of prostate cancer but 
has also reduced its mortality by 20 % (44). However, the 
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Figure 3 Relative risks of breast cancer by municipalities, Slovenia 1995-2002 (15)
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question is not whether it is effective in reducing mortality, 
but whether it does more harm than good. Compared to 
breast cancer screening in women PSA screening involves 
a significantly greater risk of overdiagnosis, unnecessary 
treatment, and eventually, lower quality of life in 
overdiagnosed patients.
Testicular cancer
Testicular cancer is, in most cases, a germ cell neoplasm. 
The incidence of testicular cancer rises with adolescence, 
and hormonal factors clearly play a role in its aetiology. 
The diagnosis peaks in the twenties and thirties. There is a 
variety of other factors that increase cancer risk, including 
height, subfertility, and exposure to endocrine disruptors. 
Some risk factors also involve exposure to hormones in 
utero (cryptorchidism, hypospadias, inguinal hernia, low 
birth weight, short gestational age, and being a twin) or to 
endogenous hormones (45). Established risk factors for 
testicular germ cell tumours also include a prior testicular 
germ cell tumour, a family history of germ cell tumour and 
various inter-sex syndromes (46, 47). There are very 
interesting migrant studies that suggest environmental and 
dietary factors. For example, the incidence of testicular 
cancer in Finland is half that in Sweden. Furthermore, the 
second generation Finnish migrants to Sweden face the 
same testicular cancer incidence as the Swedish population 
(48).
A small minority of testicular cancers, as in other 
cancers, appear to be familiar, with approximately 2 % of 
patients having an affected family member. Men with a 
first-degree relative with testicular cancer run a three to ten 
times higher risk of being diagnosed with the disease (46).
Thyroid cancer
Thyroid cancer is not as common, but its incidence has 
been increasing worldwide. This trend may be associated 
with improved screening and detection, the detection of 
papillary microcarcinoma in particular (49, 50).
Exposure to ionising radiation, especially in childhood 
(as it predisposes for papillary thyroid cancer) is among the 
well-known high risk factors for thyroid cancer. About 5 % 
of patients develop thyroid cancer due to radiation exposure 
(1, 50).
The distribution between genders is strikingly uneven, 
as the cancer affects women three to times more often than 
men (50) for reasons that may be related to hormones but 
are far from clear. An association between female hormonal 
and reproductive factors as drivers for thyroid cancer 
development has been shown in vitro but has not been 
confirmed in population-based analyses (51, 52).
According to population-based studies, thyroid cancer 
might also be moderately associated with height and body 
mass index in both genders (51). A rare clinical condition 
- acromegaly (caused by an overproduction of growth 
hormone) is also associated with increased risk of thyroid 
cancer. It is also known that thyroid cancer development is 
strongly associated with a history of benign nodules/
adenoma or goitre. Furthermore, iodine deficiency may 
induce benign thyroid conditions that predispose for thyroid 
cancer, but it is still unclear to what extent dietary iodine 
intake might serve as a risk predictor (51).
There are several rare inherited conditions (familial 
adenomatous polyposis syndrome, Cowden syndrome, 
Werner syndrome) that are associated with different types 
of thyroid cancer (53). When investigating medullary 
thyroid cancers only, about 25 % occur as part of the 
multiple endocrine neoplasia type 2 (MEN2) syndrome 
(54). MEN2 syndrome is caused by germline mutation in 
t he  RET  p ro tooncogene  and  i s  i nvo lved  i n 
phaeochromocytoma, hyperparathyroidism, and medullary 
thyroid carcinoma. RET protooncogene mutation analysis 
therefore enables predictive testing and genotype-based 
tailored prophylactic treatment and serves as a role model 
of personalised medicine, since medullary thyroid cancers 
as part of MEN 2 may be prevented by early prophylactic 
resection of the thyroid gland. 
As for non-syndromic thyroid cancer, it is estimated 
that around 10 % of all non-medullary thyroid cancers are 
hereditary, since first-degree relatives of patients with 
thyroid cancer run a ten times higher risk of thyroid cancer 
than the general population (53).
The influence of risk factors on the burden of HRCs in 
Slovenia
Risk factors for HRC are heterogeneous and are 
predominantly associated with our lifestyle, reproductive 
factors, or genetic characteristics. They can have opposite 
effects in different cancers; oral hormonal contraception 
increases the risk of breast cancer but decreases the risk of 
ovarian cancer. Even though the prevalence of HRC risk 
factors has been poorly investigated in Slovenia, we have 
enough information to explain, at least in part,  the spatial 
distribution of breast cancer risk (risk is higher in the 
western part of the country) and the rapid rise in breast and 
prostate cancer incidence. Several  studies of the 
reproductive factors in Slovenia (55-57) indicate that 
nulliparity and late first birth (which are both more prevalent 
in the west of the country) could be responsible for higher 
breast cancer risk in that part of the country. Reproductive 
risk factors in Slovenia are also central to the understanding 
of the increase in breast cancer incidence. The average age 
at first delivery and the nulliparity are increasing, and 
Slovenian women today have on average fewer children 
than earlier generations (15). The dramatic rise in prostate 
cancer incidence, in turn, is owed to dramatic rise in 
detection thanks to prostate-specific antigen (PSA) 
screening, which has been part of regular check-ups since 
the early 1990s (58).
Although reproductive and genetic factors play a major 
role in the carcinogenesis of HRCs, the contribution of 
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environmental chemicals cannot be dismissed. Endocrine 
disruptors seem to be involved in carcinogenesis through 
the same mechanisms as natural hormones. At the moment, 
however, we do not know how many of the newly diagnosed 
cancers are associated with endocrine disruptors. Further 
research should focus on assessing exposure and individual 
susceptibility, as well as latency and critical exposure 
windows. In the meantime, public health policies promote 
a precautionary approach to reasonably reduce exposure to 
endocrine-disrupting chemicals.
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Epidemiološki trendi hormonsko odvisnih rakov
Spolni hormoni so znan in pomemben nevarnostni dejavnik rakov na dojki, jajčniku in endometriju, medtem ko je njihova 
vloga pri rakih prostate in mod verjetna, a manj raziskana. Vpletenost hormonov v kancerogenezo se nakazuje tudi pri 
raku ščitnice. Predvidevamo, da se po enakih mehanizmih kot telesu lastni hormoni v nastanek raka vpletajo tudi hormonski 
motilci. Rake hormonsko odzivnih tkiv najpogosteje povezujemo z izpostavljenostjo PCB-jem in dioksinom, DDT/DDE 
ter nekaterim težkim kovinam in pesticidom. Incidenca hormonsko odvisnih rakov je največja v državah razvitega sveta. 
V Sloveniji predstavljajo hormonsko odvisni raki četrtino vseh rakov; njihovo število se z izjemo raka jajčnikov vsak 
leto veča. Tveganje raka dojk je že več desetletji večje na zahodu države, medtem ko pri ostalih lokacijah med območij 
ne opažamo pomembnih razlik. Hormonskim motilcem pripisljivega deleža rakov trenutno ni mogoče določiti, saj imamo 
verodostojnih raziskav pri izpostavljenih, predvsem v kritičnih razvojnih obdobjih, premalo.
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